Table 1.
Comparison of baseline characteristics
| Characteristics | Overall (n = 93) | TKI (n = 37) | TKI-ICI (n = 56) | P |
|---|---|---|---|---|
| Age (years) | 56 [50, 64] | 53 [49, 60] | 58.5 [51.5, 66.2] | 0.0905 |
| Sex | 0.5816 | |||
| Male | 79 (84.9) | 30 (81.1) | 49 (87.5) | |
| Female | 14 (15.1) | 7 (18.9) | 7 (12.5) | |
| ECOG (%) | 0.1081 | |||
| PS 0 | 33 (35.5) | 9 (24.3) | 24 (42.9) | |
| PS 1 | 60 (64.5) | 28 (75.7) | 32 (57.1) | |
| Cause (%) | 0.7631 | |||
| HBV | 85 (91.4) | 34 (91.9) | 51 (91.1) | |
| HCV | 4 (4.3) | 2 (5.4) | 2 (3.6) | |
| HBV + HCV | 4 (4.3) | 1 (2.7) | 3 (5.4) | |
| Surgery (%) | 21 (22.6) | 6 (16.2) | 15 (26.8) | 0.3473 |
| TACE (%) | 89 (95.7) | 35 (94.6) | 54 (96.4) | 1 |
| Ablation (%) | 62 (66.7) | 29 (78.4) | 33 (58.9) | 0.0849 |
| Number (%) | 0.5153 | |||
| ≤ 3 | 30 (32.3) | 10 (27.0) | 20 (35.7) | |
| > 3 | 63 (67.7) | 27 (73.0) | 36 (64.3) | |
| Size (%) | 0.8638 | |||
| ≤ 5 cm | 70 (75.3) | 27 (73.0) | 43 (76.8) | |
| > 5 cm | 23 (24.7) | 10 (27.0) | 13 (23.2) | |
| PVTT (%) | 37 (39.8) | 16 (43.2) | 21 (37.5) | 0.7358 |
| Metastases (%) | 41 (44.1) | 17 (45.9) | 24 (42.9) | 0.936 |
| Child–Pugh (%) | 0.6598 | |||
| Class A | 64 (68.8) | 24 (64.9) | 40 (71.4) | |
| Class B7 | 29 (31.2) | 13 (35.1) | 16 (28.6) | |
| BCLC (%) | 0.3473 | |||
| Stage B | 21 (22.6) | 6 (16.2) | 15 (26.8) | |
| Stage C | 72 (77.4) | 31 (83.8) | 41 (73.2) | |
| AFP (%) | 0.8693 | |||
| ≤ 400 ng/mL | 55 (59.1) | 21 (56.8) | 34 (60.7) | |
| > 400 ng/mL | 38 (40.9) | 16 (43.2) | 22 (39.3) | |
TKI tyrosine kinase inhibitor, ICI immune checkpoint inhibitor, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus, TACE trans-arterial chemoembolization, PVTT portal vein tumor thrombosis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein